Seegnal Benefits

Seegnal: Major benefits to providers, healthcare professionals (Clinicians), and patients

Seegnal is a comprehensive, personalized, and easy-to-use software platform that makes a difference when managing drug-related problems. It significantly reduces futile alerts to optimize the clinician’s experience and patient’s care. All this while ensuring safe drug prescription, expected clinical outcome, and a proven reduction in healthcare expenditure.

Seegnal key benefits:

Personalized and dynamic alerting
Seegnal alerts in ‘at-risk populations’ by considering hundreds of patient specific factors/modifiers (e.g., DNA profile, ECG recordings, diet, smoking, age, allergies, lab results, renal/liver functions, vital signs, drugs’ serum levels, dispensing characteristics). This enables a decrease in alert fatigue up to 95%17, 18, while generating an outstanding ratio of true-positive vs. false positive alerts17.


Backed by globally-acknowledged expertise

First Data Bank (FDB) – a comprehensive & professional screening tool, which focuses on the clinical relevance of potential interactions

DIDB Platform, University of Washington – relying on the unique know-how of DIDB (Pharmacokinetic Database) & ePKGene (Pharmacogenetic Database) as well as incorporating the use of mechanism-based inference in order to personalize the assessments

Hansten & Horn Publications – advice from globally acknowledged drug interaction specialists


One glance operation
An innovative graphic user interface that enables, in seconds, to promptly detect, prioritize and solve DRPs.


Very high sensitivity and specificity ratio17; Alert fatigue minimization

Derived from a unique, 3-tier mechanism that generates a high true-positive vs false-positive alerting ratio while substantially decreasing alert load. This is in contrast to a very high ‘Noise-to-Signal’ alert ratio in current solutions.


Alternative drug(s) mechanism
Seegnal presents alternative drug(s) to problematic combinations, based on its unique mechanism and by considering various patient associated factors. The alternatives are sorted by their potential to generate alerts/safety issues.


Multi-drug assessment of designated interactions
In contrary to binary assessments.


Substantial impact on healthcare/economics
Proven to reduce hospitalizations (-5.6%), drug consumption (-1.5%) & imaging procedures (-2.1%)16.     



16. Large-scale, community-based trial of a personalized drug-related problem rectification system. kahan et al., American Journal of Pharmacy Benefits 2017; 9(2):41-6.

17. Meuhedet Health Services (Israel)  – Analysis of 300 polypharmacy patients; Nov 2016. In-house; Data (unpublished) from Meuhedet.

18. Leumit Health Services, Israel – Analysis of Aug 1-10, 2016 real-time alerts distribution. In-house data